A follow-up Phase II open-label study to evaluate the long-term safety and efficacy profile of ABX464 given at 25 mg once daily in subjects with Moderate to Severe Active Ulcerative Colitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507974-42-00

Acronym

ABX464-108

Enrollment

161

Registered

2024-06-11

Start date

2021-12-01

Completion date

Unknown

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate to Severe Ulcerative Colitis

Brief summary

Number of Adverse Events (AEs) in ABX464 treated subjects.

Interventions

DRUGABX464

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of Adverse Events (AEs) in ABX464 treated subjects.	—

Countries

Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Slovakia, Slovenia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026